- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Secondary progressive multiple sclerosis (SPMS)
- Meeting Date: November 2019
- Public Summary Document (PSD) November 2019 PBAC Meeting - (PDF 706KB)
- Public Summary Document (PSD) November 2019 PBAC Meeting - (Word 181KB)
Siponimod – November 2019
Siponimod: Tablet 250 micrograms, Tablet 2 mg; Mayzent®
Last updated
20 March 2020